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ment of disease (as seen with dengue virus) may occur with Zika,
although data suggest that Zika virus exists as a single serotype
(Dowd et al., 2016). Despite the challenges, it is imperative that we de-
velop vaccines against Zika that can be effectively used in developing
countries and that are safe for use in pregnant women.Zika virus
VaccineApproximately 70 years ago, new ﬂavivirus was discovered in the
Zika forest of Uganda (Dick et al., 1952). The eponymous virus is an ar-
thropod-borne human pathogen that caused infrequent infections with
relatively mild illness in Africa and received relatively little attention
until recently. Over the last several years the virus has spread into
Southeast Asia, across the Paciﬁc and, in 2015, into Brazil causing larger
and larger outbreaks. Most infected individuals (~80%) are asymptom-
atic, while those who develop clinical disease display short-lived symp-
toms including: rash, fever, arthralgia, and conjunctivitis (Barzon et al.,
2016). Unfortunately, the recent outbreaks have corresponded with in-
creased rates of severe fetal neurological defects, fetal malformations,
and Guillain-Barre syndrome and subsequent studies have causally
linked Zika virus to these serious clinical outcomes (Cao-Lormeau et
al., 2016; Johansson et al., 2016).More recently, outbreaks have been re-
ported in over 60 countries, with well over 1 million cases in, Brazil
alone, leading theWHO to declare Zika a global public health emergen-
cy. Zika virus has been demonstrated to spread through sex and transfu-
sionwith blood produces, and to be transmitted from themother to the
fetus.
The development of a safe and effective vaccine against Zika virus is
a public health priority, however several challenges stand in our way.
First, relatively little is known about Zika virus biology or immunity. For-
tunately, other ﬂaviviruses such as yellow fever virus, dengue virus, and
Japanese encephalitis virus have been well studied, and have existing
vaccines with a wealth of immunogenicity and efﬁcacy data which can
serve as starting model systems as Zika-focused research efforts come
online. Second, the need to protect women who are pregnant or areom.2016.09.028.
. This is an open access article underattempting to become pregnant introduces complications into formu-
lating and testing new vaccines. Third, antibody dependent enhance-
Multiple vaccine candidates are currently in various stages of re-
search and development (Tripp and Ross, 2016). Many of these are
based on existing platforms known to be effective for other pathogens
and include: inactivated viral particles, nucleic acid (DNA and RNA) vac-
cines, live vectored vaccines based (e.g., measles, vaccinia, and adenovi-
rus), chimeric vaccines, and subunit vaccines based on individual Zika
virus proteins. A recent study by Larocca et al. studied the effect of
two Zika vaccines, a plasmid DNA vaccine expressing the prM and Env
proteins and a puriﬁed, formalin-inactivated vaccine, in immunocom-
petent mice. A single dose of either vaccine elicited robust protective
immunity in all mouse strains tested (Larocca et al., 2016). A follow-
up study by Abbink et al., demonstrated robust immune responses
and protective efﬁcacy of the same two vaccines in rhesus macaques
(Abbink et al., 2016). The same study went on to test a rhesus adenovi-
rus serotype 52 vector-based vaccine which was also highly immuno-
genic and protective against live virus challenge. So far, two Zika
vaccines are in phase I clinical trials (NCT02840487 andNCT02887482).
In this issue of EBioMedicine, Kim et al., report the on the early stage
development of two Zika vaccines (Kim et al., 2016). The ﬁrst vaccine is
an adenovirus serotype 5-vectored vaccine expressing the Zika E pro-
tein (Ad5.ZIKV-Eﬂ vaccine) derived from a Brazilian isolate
(BeH815744). The second formulation is a subunit recombinant E pro-
tein vaccine delivered by carboxymethylcellulose microneedle array
(MNA-ZIKV-rEﬂ). In both cases the Zika E proteinwas fused to the T4 ﬁ-
brin foldon trimerization domain. The authors demonstrate that a
prime-boost vaccination regimen of the Ad5.ZIKV-Eﬂ vaccine elicits
high titer neutralizing antibody in C57BL/6 mice. A major goal of any
Zika vaccine is to prevent infection and/or neurologic impairment of
the fetus, therefore the authors tested a passive protection suckling
mouse model. In this model Ad5.ZIKV-Eﬂ vaccinated females are
mated with unvaccinatedmales and pups are challenged intraperitone-
ally with a heterologous Zika strain (DAKAR41542) at 7 days after birth.
100% of the pups from unvaccinated mothers develop disease with
physical and neurological manifestations. Pups from mothers immu-
nized with the Ad5.ZIKV-Eﬂ vaccine displayed complete protection
with 100% survival and no clinical evidence of disease. Furthermore,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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birth. In contrast, the subunit vaccine delivered by microneedle array
(MNA-ZIKV-rEﬂ)was considerably less immunogenic.While it did elicit
a humoral response in recipient mice, the response kinetics were de-
layed and the absolute magnitude of the response was considerably
lower as neutralizing titers at 6 weeks post-priming were 10-fold less
than those in the mice immunized with the Ad5.ZIKV-Eﬂ vaccine.
Pups born to MNA-ZIKV-rEﬂ immunized mothers were partially
protected in that weight loss was signiﬁcantly less than in the PBS-im-
munized controls, however 5/6 MNA-ZIKV-rEﬂ immunized mice still
displayed signs of neurological disease, although the severity score
was signiﬁcantly lower. Furthermore, the survival rate for pups of
MNA-ZIKV-rEﬂ vaccinated mothers was only 50% after viral challenge.
Lastly, neutralizingAb titers in the pups had decreased to baseline levels
by day 25.
The data from this study make important contributions to our
knowledge of immune responses to Zika virus and to the development
of effective vaccines against Zika. The authors utilized puriﬁed E protein,
whichwas characterized by low protein yields, indicating that prMpro-
teinmay be required for optimal stability and that prM-Emay be amore
effective antigen. The effect of E protein trimerizationwas not speciﬁcal-
ly evaluated in this study and may serve as another useful technique to
enhance protein production, stability, and immunogenicity. A large per-
centage of the human population possesses Ad5-speciﬁc antibodies,
thereby limiting the usefulness of Ad5.ZIKV-Eﬂ vaccine in humans. Nev-
ertheless, the Ad5.ZIKV-Eﬂ vaccine data are impressive and clearly dem-
onstrate the robust immunogenicity of this platform, especially in light
of the previously cited report (Larocca et al., 2016) using rhesus adeno-
virus vector for which this complication is minimized. The MNA-ZIKV-
rEﬂ vaccine data is less impressive but potentially of greater value. The
MNA-vaccine platform has multiple production advantages: reproduc-
ibility, low cost and ease of manufacturing, product stability, the poten-
tial to require lower doses of antigen, simpliﬁed and painless
vaccination procedure, the possible elimination of the cold chain stor-
age needs. The system is amenable to the introduction of adjuvants
that can be lyophilized and encapsulated in the microneedle array
(i.e., TLR ligands or cytokines). The goals of this study and themodel sys-
tem used to evaluate protection are important in light of the impact of
Zika infection on the developing fetus. Future work evaluating these
vaccines in additional animal models (e.g., A129, AG129, SJL mice)
may provide important additional information regarding these two vac-
cine platforms.
A number of knowledge gaps concerning Zika virus still exist, posing
questions that need to be answered in order to fully control this disease
(Thomas et al., 2016). These gaps include: the How, Why, and When of
Zika outbreaks, the risk factors for different clinical disease, the effects ofco-infections with other arboviruses, details about transmission routes,
the timing of risk during pregnancy, how age, immunocompetence,
race, gender, and genetics effect disease susceptibility or clinical out-
come, the development of safety and efﬁcacy data in pregnant
women, the degree of cross-reactivity of vaccine strains, the develop-
ment of appropriate animal models accurately reﬂecting human dis-
ease, and the establishment of correlates of protection in humans to
name a few. Fortunately, the global health community has come togeth-
er to combat this global problem. The provision of adequate resources in
terms of funding, infrastructure, manpower, and long-lived commit-
ment to the goal on the part of government, private industry, academia
and other organizations will be essential if we are to eventually control
this disease.
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